When people go to #jail or #prison, their #health issues go with them, but treating this unique patient population carries complex challenges, such as high costs, gaps in care, and communication challenges between on-site physicians and specialists: ow.ly/xZ2Q50StJ0b

In a nationwide screening study for individuals at high risk for #MultipleMyeloma #MM, those with an elevated #BMI, low levels of physical activity, heavy smoking, or short sleep were more likely to have #MGUS detected by mass spectrometry: ow.ly/olgZ50StGlR

As recent trials of #FLT3 inhibitors for #AML have shown improvements in survival when paired with induction chemotherapy, there's no longer a question of whether to incorporate them, but which one to use. Which FLT3 inhibitor do you feel is most effective in treating AML?

Recent research from JACC Journals #JACCCardioOnc indicates that use of an #AI ECG algorithm could help predict the risk of #AtrialFibrillation in patients with newly diagnosed #ChronicLymphocyticLeukemia #CLL: ow.ly/bJHW50SxmiA

Our new episode on management of polycythemia vera with Aaron Gerds MD, MS is out! Tune in for a wide-ranging discussion on diagnosis, risk-stratification, and management of PV. tinyurl.com/4bu2pfe5 Here is a clip on the role of BM aspiration/biopsy in PV diagnosis! Ashwin Kishtagari, MD

When compared with all-trans retinoic acid (ATRA) plus #chemotherapy, the regimen of ATRA plus arsenic trioxide demonstrated superior event-free survival among patients with high-risk #AcutePromyelocyticLeukemia: ow.ly/6AHi50SCk86 #EHA24

Want to learn about the use of #menin inhibitors in #AcuteMyeloidLeukemia #AML? Join our webinar on August 7 to hear from key experts on the latest findings in the development of menin inhibitors and recent trials. Find more information and register at ow.ly/Tac050SOjHh

Join me in participating in one of the greatest demonstrations of democracy we have -- the ASH elections! 🩸🩸🩸Now open at vote.escvote.com/ash! Check your email for your member# and PIN!

According to findings from a retrospective study in Blood Neoplasia, a significant portion of patients in their 80s and 90s with #AcuteMyeloidLeukemia #AML can live longer if they are treated with dose-modified #venetoclax plus a hypomethylating agent: ow.ly/16lN50T59Mw

Three generations- dedication, passion for supporting ⁦VeloSano⁩ thank you ⁦Aaron Gerds MD, MS⁩ !! ⁦Cleveland Clinic⁩ ⁦Cleveland Clinic MD⁩ !!

#mpnsm meeting underway! Naveen Pemmaraju, MD PedsHemeDoc Ruben A. Mesa, MD Raajit Rampal, M.D.Ph.D. #andmanymore!

👉👉👉Marvelous faculty dinner together at River Cafe ! #MPNSM #NYC #Brooklyn | PedsHemeDoc

Excited to have #OncLiveSSOS underway here in the #CLE! OncLive.com Akriti Jain Abhay Singh Cleveland Clinic MD Case Comp Cancer Ctr

Looking Forward: Advances and Obstacles in Blood Cancer Treatment consultqd.clevelandclinic.org/looking-forwar… via @clevelandclinic Aaron Gerds MD, MS OncoAlert Hetty Carraway

According to findings to be presented at #ASH24, reduced #DOAC dosing was found to be associated with a decreased #bleeding rate and lower #healthcare utilization in the setting of secondary prevention of #VTE: ow.ly/Nx6L50UmzMS

#ASH24 Among patients with heavily pretreated, R/R #ChronicLymphocyticLeukemia, treatment with the #bispecific antibody #epcoritamab led to high rates of overall and complete response, as well as a high rate of uMRD: ow.ly/kZ4k50UmYFa

Past ASH memories! #ASH24 ASH Ruben A. Mesa, MD James Blachly Mikkael A. Sekeres MD, MS Joseph Mikhael

Congrats to Dr. Natalie Wuliji of Fred Hutch Cancer Center at #ASH24 for a wonderful plenary discussion! This study examined socioeconomic factors of patients undergoing #bmt for #AML. Honored to be a part of it. Cleveland Clinic Sudipto Mukherjee MD PhD MPH

Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to data presented at #ASH24. Healio spoke with Aaron Gerds MD, MS of Case Comp Cancer Ctr about the findings. #AML #Leukemia healio.com/news/hematolog…

Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis consultqd.clevelandclinic.org/positive-resul… via @clevelandclinic Aaron Gerds MD, MS Cleveland Clinic MD Cleveland Clinic